The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
|Articles|January 22, 2013
Mini-quiz: Movement Disorders
Movement abnormalities and psychiatric symptoms often overlap and exacerbate one another. Can psychopharmacological agents induce movement disorders?
Advertisement
Comorbidity occurs across a broad range of conditions and in a wide variety of circumstances. Can psychopharmacological agents induce movement disorders?
For the answer,
Answer: True
Discussion:
The overall prevalence of movement disorders associated with psychiatric disorders is unknown and difficult to estimate. However, movement disorders that have a prominent tremor component can be worsened by pharmacological treatment of psychiatric conditions.
For more on this topic, please see "
Advertisement
Related to this article
An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
5